CN2 COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK
نویسندگان
چکیده
منابع مشابه
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
AIM To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant temozolomide with radiotherapy for the treatment of newly diagnosed glioblastoma compared with initial radiotherapy alone. METHODS Electronic databases were searched for relevant publications on costs and cost-effectiveness until October 2008. RESULTS We found four relevant clinical trials, on...
متن کاملCurrent Advances in Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
Copyright: © 2014 Okonogi N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
متن کاملLongitudinal MRSI study in newly diagnosed Glioblastoma Multiforme
Introduction Glioblastoma Multiforme (GBM) is the most common and the most malignant type of glioma. Despite the advances in multimodality treatments that combine surgery, radiation and chemotherapy, patients with GBM have a limited prognosis, with a median survival of one year. The standard criteria for assessing tumor progression and response to therapy are based upon changes in cross section...
متن کاملConcomitant temozolomide and radiotherapy versus radiotherapy alone for treatment of newly diagnosed glioblastoma multiforme.
PURPOSE To study the efficacy and safety of radiotherapy (RT) with concomitant and subsequent temozolomide in comparison to RT alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) after brain surgical intervention. METHODS Twenty patients received cranial fractionated RT (60 Gy total dose: 2 Gy/day, 5 days/week, for 6 weeks) with concomitant oral temozolomide ...
متن کاملAdvances in the treatment of newly diagnosed glioblastoma
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2005
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)67204-x